Canada-based Contract Research Organization (CRO) Pegasus Biotech Inc., announced a strategic collaboration with the Vaccine and Infectious Disease Organization (VIDO) at the University of Saskatchewan to advance the development and commercialization of Pegasus’s BPE DNA platform for next-generation biologics. The agreement, formalized as a memorandum of understanding, establishes a three-year framework intended to connect Pegasus’s plasmid DNA technology with VIDO’s manufacturing capabilities and infectious disease research infrastructure.
The collaboration sees Pegasus apply its BPE plasmid development expertise, while VIDO contributes manufacturing capabilities, laboratory facilities, and its established position in vaccine development and infectious disease science. The memorandum of understanding does not itself constitute an agreement; specific projects will be defined and governed under separate agreements negotiated within the three-year framework.
The stated application areas for the BPE DNA platform span animal vaccines, human vaccines, gene therapy, and drug delivery. The BPE DNA platform is a plasmid DNA manufacturing technology designed to produce constructs in bacterial systems that are optimized for expression in eukaryotic, meaning mammalian or animal, cells. Plasmid DNA serves as a foundational material across several application categories, including as a direct therapeutic or vaccine construct, as a template for messenger RNA synthesis, and as a raw material for viral vector production used in gene therapy workflows. The platform’s multi-application architecture positions it across several areas of the biologics supply chain simultaneously.
The practical gap the Pegasus Biotech VIDO collaboration addresses is the transition from laboratory-scale platform development to manufacturing-scale, application-validated production. For Pegasus’s clients, this gap represents a substantive barrier between early-stage platform work and commercial readiness. VIDO’s role in the arrangement is to provide the infrastructure and scientific credibility needed to support that transition, particularly in vaccine-related applications where the organization holds an established international profile.
VIDO, operating within the University of Saskatchewan, has a history in infectious disease research and vaccine development that spans several decades and multiple pathogen programs. The organization has developed manufacturing and containment capabilities that support work across a range of biological risk categories, giving it a profile that extends beyond standard academic research institutions. That operational depth is the primary asset Pegasus is accessing through the memorandum of understanding.
The broader context for this type of platform collaboration reflects conditions in the plasmid DNA supply and manufacturing space that have developed over several years. Demand for GMP-grade plasmid DNA has grown alongside the expansion of gene therapy clinical programs, cell therapy manufacturing workflows, and nucleic acid vaccine development. Plasmid DNA is a critical input material for adeno-associated virus vector production, lentiviral vector manufacturing, and CAR-T cell therapy processes, and supply constraints have been documented across the field. Platforms capable of delivering consistent, scalable, regulatory-compliant plasmid DNA have attracted attention from developers seeking to secure reliable upstream supply. Yimy Mena, Chief Executive Officer of Pegasus Biotech, described the collaboration as a step toward strengthening the company’s ability to support clients in moving products closer to commercialization, citing the combination of VIDO’s expertise, manufacturing capabilities, and infrastructure as central to that objective.